patocka.xml

Obsah souboru

<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Publisher PUBLIC "-//MetaPress//DTD MetaPress 2.0//EN" "http://public.metapress.com/dtd/MPRESS/MetaPressv2.dtd">
<Publisher>
	<PublisherInfo>
		<PublisherName>University of South Bohemia, Ceske Budejovice and Versita, Warsaw</PublisherName>
	</PublisherInfo>
	<Journal>
		<JournalInfo JournalType="Journals">
			<JournalPrintISSN>1214-021X</JournalPrintISSN>
			<JournalElectronicISSN>1214-0287</JournalElectronicISSN>
			<JournalTitle>Journal of Applied Biomedicine</JournalTitle>
			<JournalCode>JAB</JournalCode>
			<JournalID>121649</JournalID>
			<JournalURL>http://versita.metapress.com/link.asp?target=journal&amp;id=121649</JournalURL>
		</JournalInfo>
		<Volume>
			<VolumeInfo>
				<VolumeNumber>8</VolumeNumber>
			</VolumeInfo>
			<Issue>
				<IssueInfo IssueType="Regular">
					<IssueNumberBegin>1</IssueNumberBegin>
					<IssueNumberEnd>1</IssueNumberEnd>
					<IssueSupplement>0</IssueSupplement>
					<IssuePartStart>0</IssuePartStart>
					<IssuePartEnd>0</IssuePartEnd>
					<IssueSequence>000008000120100101</IssueSequence>
					<IssuePublicationDate>
						<CoverDate Year="2010" Month="1" Day="1"/>
						<CoverDisplay>Number 1 / January 2010</CoverDisplay>
					</IssuePublicationDate>
					<IssueID>W87G74W522V0</IssueID>
					<IssueURL>http://versita.metapress.com/link.asp?target=issue&amp;id=W87G74W522V0</IssueURL>
				</IssueInfo>
				<Article ArticleType="Original">
					<ArticleInfo Free="No" ESM="No">
						<ArticleDOI>10.2478/v10136-009-0002-z</ArticleDOI>
						<ArticlePII>0025715218548846</ArticlePII>
						<ArticleSequenceNumber>2</ArticleSequenceNumber>
						<ArticleTitle Language="En">Biomedically relevant chemical constituents of &lt;i&gt;Valeriana officinalis&lt;/i&gt;</ArticleTitle>
						<ArticleFirstPage>11</ArticleFirstPage>
						<ArticleLastPage>18</ArticleLastPage>
						<ArticleHistory>
							<RegistrationDate>20100127</RegistrationDate>
							<ReceivedDate>20100127</ReceivedDate>
							<Accepted>20100127</Accepted>
							<OnlineDate>20100127</OnlineDate>
						</ArticleHistory>
						<FullTextFileName>0025715218548846.pdf</FullTextFileName>
						<FullTextURL>http://versita.metapress.com/link.asp?target=contribution&amp;id=0025715218548846</FullTextURL>
						<Composite>1</Composite>
					</ArticleInfo>
					<ArticleHeader>
						<AuthorGroup>
							<Author AffiliationID="A1">
								<GivenName>Jiří</GivenName>
								<Initials/>
								<FamilyName>Patočka</FamilyName>
								<Degrees/>
								<Roles/>
							</Author>
							<Author AffiliationID="A2">
								<GivenName>Jiří</GivenName>
								<Initials/>
								<FamilyName>Jakl</FamilyName>
								<Degrees/>
								<Roles/>
							</Author>
							<Affiliation AFFID="A1">
								<OrgDivision/>
								<OrgName>Department of Radiology and Toxicology, Faculty of Health and Social Studies, University of South Bohemia České Budějovice, Czech Republic</OrgName>
								<OrgAddress/>
							</Affiliation>
							<Affiliation AFFID="A2">
								<OrgDivision/>
								<OrgName>Department of Dendrology and Forest Tree Breeding, Faculty of Forestry and Wood Sciences, Czech University of Life Sciences, Prague, Czech Republic</OrgName>
								<OrgAddress/>
							</Affiliation>
						</AuthorGroup>
						<Abstract Language="En">Valerian is used to treat sleeping disorders, restlessness and anxiety, but it seems only to work when taken over long periods (several weeks). Some studies have demonstrated that valerian extracts interact with the GABA and benzodiazepine receptors. Valerian is also used traditionally to treat gastrointestinal pain and spastic colitis. There are no long term safety studies. Valerian contains over 150 chemical constituents and many of them are physiologically active, mainly pyridine alkaloids, some organic acids and terpenes, especially the so called valepotriates, esterified iridoid-monoterpenes. As valepotriates may be potential mutagens, valerian should only be used after consultation with a physician. Valerian medication is sometimes recommended as first line treatment when the benefit-risk relation requires it and is often indicated as transition medication during the discontinuation processes involving bromazepam, clonazepam and diazepam, among others.</Abstract>
						<KeywordGroup Language="En">
							<Keyword>&lt;i&gt;Valeriana officinalis&lt;/i&gt;</Keyword>
						</KeywordGroup>
						<KeywordGroup Language="En">
							<Keyword>valerian</Keyword>
						</KeywordGroup>
						<KeywordGroup Language="En">
							<Keyword>chemical constituents</Keyword>
						</KeywordGroup>
						<KeywordGroup Language="En">
							<Keyword>alkaloids</Keyword>
						</KeywordGroup>
						<KeywordGroup Language="En">
							<Keyword>terpenes</Keyword>
						</KeywordGroup>
						<KeywordGroup Language="En">
							<Keyword>valepotriates</Keyword>
						</KeywordGroup>
					</ArticleHeader>
				</Article>
			</Issue>
		</Volume>
	</Journal>
</Publisher>